{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:44:44Z","timestamp":1648795484507},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,10,27]],"date-time":"2013-10-27T00:00:00Z","timestamp":1382832000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s11886-013-0428-5","type":"journal-article","created":{"date-parts":[[2013,10,26]],"date-time":"2013-10-26T07:24:40Z","timestamp":1382772280000},"source":"Crossref","is-referenced-by-count":0,"title":["Medical Treatment of Hypertension in Patients with Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1007","volume":"15","author":[{"given":"Richard G.","family":"Kiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,27]]},"reference":[{"key":"428_CR1","doi-asserted-by":"crossref","unstructured":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics\u20132010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46.","DOI":"10.1161\/CIRCULATIONAHA.109.192667"},{"key":"428_CR2","doi-asserted-by":"crossref","unstructured":"Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387.","DOI":"10.1161\/hc1102.105289"},{"key":"428_CR3","doi-asserted-by":"crossref","unstructured":"Davis BR et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118(22):2259\u201367.","DOI":"10.1161\/CIRCULATIONAHA.107.762229"},{"key":"428_CR4","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Piller LB et al. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011;124(17):1811\u20138. The ALLHAT study is one of the strongest studies to date comparing the efficacy of various classes of antihypertensives, evaluating the relative efficacy of chlorthalidone, amlodipine, and lisinopril.","DOI":"10.1161\/CIRCULATIONAHA.110.012575"},{"key":"428_CR5","doi-asserted-by":"crossref","unstructured":"Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ. 434 Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2: 435 CD003838.","DOI":"10.1002\/14651858.CD003838.pub3"},{"key":"428_CR6","doi-asserted-by":"crossref","unstructured":"Verdecchia P et al. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens. 2006;19:493\u20139.","DOI":"10.1016\/j.amjhyper.2005.10.018"},{"key":"428_CR7","doi-asserted-by":"crossref","unstructured":"Okin PM et al. Losartan intervention for endpoint reduction in hypertension study investigators: regression of electrogardiographic left ventricular hypertrophy by losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation. 2003;108:684\u201390.","DOI":"10.1161\/01.CIR.0000083724.28630.C3"},{"key":"428_CR8","doi-asserted-by":"crossref","unstructured":"Dahlof B et al. for the LIFE study group: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995\u20131003.","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"428_CR9","doi-asserted-by":"crossref","unstructured":"Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment of left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41.","DOI":"10.1016\/S0002-9343(03)00158-X"},{"key":"428_CR10","doi-asserted-by":"crossref","unstructured":"Burns J et al. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens. 2012;30:2039\u201346.","DOI":"10.1097\/HJH.0b013e328356b850"},{"key":"428_CR11","doi-asserted-by":"crossref","unstructured":"Shaw RV, Akshay SD, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010;16(3):260\u20137.","DOI":"10.1016\/j.cardfail.2009.11.007"},{"issue":"3","key":"428_CR12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flatcher","year":"2005","unstructured":"Flatcher MD et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215.","journal-title":"Eur Heart J"},{"issue":"8","key":"428_CR13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"\u2022 Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction \u2013 The Aldo-DHF randomized control trial. JAMA. 2013;309(8):781\u201391. Aldo-DHF was a highy anticipated study looking at the efficacy of spironolactone on improving outcomes in patents with HFPEF. Ultimately, despite an demonstrated improvement in LV diastolic function the study failed to demonstrate any clinically significant benefits.","journal-title":"JAMA"},{"key":"428_CR14","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"P Bertram","year":"2003","unstructured":"Bertram P et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy study. Circulation. 2003;108:1831\u20138.","journal-title":"Circulation"},{"issue":"4","key":"428_CR15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.amjcard.2004.05.004","volume":"94","author":"Y Takeda","year":"2004","unstructured":"Takeda Y et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol. 2004;94(4):448\u201353.","journal-title":"Am J Cardiol"},{"key":"428_CR16","doi-asserted-by":"crossref","unstructured":"Hernandez AF, Hammill BG, O\u2019Connor CM, Shulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Life Saving Treatment in Hospitalized Patients with Heart Failure) registry. J Am Coll Cardiol. 2009;53(2):184.","DOI":"10.1016\/j.jacc.2008.09.031"},{"key":"428_CR17","doi-asserted-by":"crossref","unstructured":"Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990;66(12):981\u20136.","DOI":"10.1016\/0002-9149(90)90937-V"},{"key":"428_CR18","doi-asserted-by":"crossref","unstructured":"Bonow RO, Dilxizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic feeling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short-and long-term effects. Circulation. 1985;72(4):853.","DOI":"10.1161\/01.CIR.72.4.853"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-013-0428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-013-0428-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-013-0428-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T10:22:38Z","timestamp":1564568558000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-013-0428-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,27]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1007\/s11886-013-0428-5","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,27]]},"article-number":"428"}}